Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Grifols.

Clinical Briefings™: Optimizing Management of Patients With PID Disorders- Challenges and Opportunities in Diagnosis and Treatment

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview of the management of primary immune deficiency disorders (PIDDs), diagnostic evaluation of patients with these conditions, and the efficacy and safety of therapies recommended for the treatment of PIDDs. The multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Grifols.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is intended for allergists, immunologists, critical care specialists, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of PIDDs.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review the most prevalent types of PIDDs and their associated characteristics and disease burden
  • Discuss strategies for effective diagnosis of PIDDs to enable timely therapeutic intervention
  • Evaluate the efficacy and safety of IVIG and SCIG therapies for management of patients with PIDDs
  • Develop treatment strategies for special populations with PIDDs

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Richard L. Wasserman, MD, PhD
Richard L. Wasserman, MD, PhD
Medical Director of Pediatric Allergy and Immunology
Medical City Children’s Hospital
Dallas, TX

Disclosures: Grant/Research Support: CSL Behring, Evolve Biosystems, Grifols, GC Pharma, Takeda; Consultant: CSL Behring, Evolve Biosystems, GC Pharma, Takeda; Speaker’s Bureau: CSL Behring, Grifols, Takeda.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By